SE0300207D0 - New use and composition - Google Patents

New use and composition

Info

Publication number
SE0300207D0
SE0300207D0 SE0300207A SE0300207A SE0300207D0 SE 0300207 D0 SE0300207 D0 SE 0300207D0 SE 0300207 A SE0300207 A SE 0300207A SE 0300207 A SE0300207 A SE 0300207A SE 0300207 D0 SE0300207 D0 SE 0300207D0
Authority
SE
Sweden
Prior art keywords
composition
new use
digalactosyldiacylglycerol
wounds
bilayer
Prior art date
Application number
SE0300207A
Other languages
English (en)
Swedish (sv)
Inventor
Mona Staahle-Baeckdahl
Johan Heilborn
Conny Bogentoft
Anders Carlsson
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20290232&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0300207(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to SE0300207A priority Critical patent/SE0300207D0/xx
Publication of SE0300207D0 publication Critical patent/SE0300207D0/xx
Priority to US10/543,659 priority patent/US7452864B2/en
Priority to PCT/SE2004/000111 priority patent/WO2004067025A1/en
Priority to ES04705973.8T priority patent/ES2467090T3/es
Priority to CN201510400952.7A priority patent/CN105079784B/zh
Priority to SI200432154T priority patent/SI1589987T1/sl
Priority to PT47059738T priority patent/PT1589987E/pt
Priority to EP04705973.8A priority patent/EP1589987B1/en
Priority to CN2004800032098A priority patent/CN1744913B/zh
Priority to JP2006502781A priority patent/JP4750690B2/ja
Priority to DK04705973.8T priority patent/DK1589987T3/da
Priority to CA2513598A priority patent/CA2513598C/en
Priority to CN201010150582A priority patent/CN101838326A/zh
Priority to ZA200505830A priority patent/ZA200505830B/en
Priority to US12/232,215 priority patent/US8012933B2/en
Priority to US13/193,131 priority patent/US8506994B2/en
Priority to US13/938,120 priority patent/US8936807B2/en
Priority to CY20141100342T priority patent/CY1115142T1/el
Priority to US14/567,267 priority patent/US9125875B2/en
Priority to HK16105830.5A priority patent/HK1217661A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
SE0300207A 2003-01-29 2003-01-29 New use and composition SE0300207D0 (sv)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE0300207A SE0300207D0 (sv) 2003-01-29 2003-01-29 New use and composition
CA2513598A CA2513598C (en) 2003-01-29 2004-01-28 Use of the cathelicidin ll-37 and derivatives thereof for wound healing
CN201010150582A CN101838326A (zh) 2003-01-29 2004-01-28 Cathelicidin ll-37及其衍生物在伤口愈合中的用途
EP04705973.8A EP1589987B1 (en) 2003-01-29 2004-01-28 Use of the cathelicidin ll-37 peptide derivatives thereof for use in treating chronic wounds
DK04705973.8T DK1589987T3 (da) 2003-01-29 2004-01-28 Anvendelse af cathelicidin ll-37 peptid-derivativer til behandling af kroniske sår
ES04705973.8T ES2467090T3 (es) 2003-01-29 2004-01-28 Uso de péptidos derivados de la catelicidina LL-37 para usar en el tratamiento de heridas crónicas
CN201510400952.7A CN105079784B (zh) 2003-01-29 2004-01-28 Cathelicidin ll-37及其衍生物在伤口愈合中的用途
SI200432154T SI1589987T1 (sl) 2003-01-29 2004-01-28 Uporaba katelicidin ll-37 peptidnih derivatov za uporabo pri zdravljenju kroniäśnih ran
PT47059738T PT1589987E (pt) 2003-01-29 2004-01-28 Uso do péptido ll-37 de catelicidina e seus derivados no tratmento de feridas crónicas
US10/543,659 US7452864B2 (en) 2003-01-29 2004-01-28 Use of the cathelicidin LL-37 and derivatives thereof for wound healing
CN2004800032098A CN1744913B (zh) 2003-01-29 2004-01-28 Cathelicidin ll-37及其衍生物在伤口愈合中的用途
JP2006502781A JP4750690B2 (ja) 2003-01-29 2004-01-28 創傷治癒のための、カテリシジンｌｌ−３７、および、それらの誘導体の使用
PCT/SE2004/000111 WO2004067025A1 (en) 2003-01-29 2004-01-28 Use of the cathelicidin ll-37 and derivatives thereof for wound healing
ZA200505830A ZA200505830B (en) 2003-01-29 2005-07-20 Use of the cathelicidin LL-37 and derivatives thereof for wound healing
US12/232,215 US8012933B2 (en) 2003-01-29 2008-09-12 Use of the cathelicidin LL-37 and derivatives therof for wound healing
US13/193,131 US8506994B2 (en) 2003-01-29 2011-07-28 Use of the cathelicidin LL-37 and derivatives thereof for wound healing
US13/938,120 US8936807B2 (en) 2003-01-29 2013-07-09 Use of the cathelicidin LL-37 and derivatives thereof for wound healing
CY20141100342T CY1115142T1 (el) 2003-01-29 2014-05-15 Χρηση πεπτιδιων παραγωγων της καθελισιδινης ll-37 για τη θεραπεια χρονιων πληγων
US14/567,267 US9125875B2 (en) 2003-01-29 2014-12-11 Use of the cathelicidin LL-37 and derivatives thereof for wound healing
HK16105830.5A HK1217661A1 (zh) 2003-01-29 2016-05-23 及其衍生物在傷口癒合中的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300207A SE0300207D0 (sv) 2003-01-29 2003-01-29 New use and composition

Publications (1)

Publication Number Publication Date
SE0300207D0 true SE0300207D0 (sv) 2003-01-29

Family

ID=20290232

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300207A SE0300207D0 (sv) 2003-01-29 2003-01-29 New use and composition

Country Status (14)

Country Link
US (5) US7452864B2 (da)
EP (1) EP1589987B1 (da)
JP (1) JP4750690B2 (da)
CN (3) CN101838326A (da)
CA (1) CA2513598C (da)
CY (1) CY1115142T1 (da)
DK (1) DK1589987T3 (da)
ES (1) ES2467090T3 (da)
HK (1) HK1217661A1 (da)
PT (1) PT1589987E (da)
SE (1) SE0300207D0 (da)
SI (1) SI1589987T1 (da)
WO (1) WO2004067025A1 (da)
ZA (1) ZA200505830B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
WO2004098536A2 (en) * 2003-03-06 2004-11-18 The Regents Of The University Of California Anti-viral activity of cathelicidin peptides
AU2004262002B2 (en) * 2003-08-01 2010-03-25 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
RU2358753C2 (ru) 2003-08-07 2009-06-20 Хилор Лтд. Фармацевтические композиции и способы для ускорения заживления ран
US7776823B2 (en) * 2003-10-21 2010-08-17 The Regents Of The University Of California Human cathelicidin antimicrobial peptides
SE0401942D0 (sv) * 2004-07-28 2004-07-28 Lipopeptide Ab New antimicrobial peptide complexes
EP1846444A2 (en) 2004-12-22 2007-10-24 Lipopeptide AB Agents inhibiting the cathelin-like protein cap18/ll-37
DK1888033T3 (da) * 2005-06-09 2014-05-26 Meda Ab Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
US9044438B2 (en) 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
NZ566083A (en) 2005-08-29 2012-11-30 Healor Ltd Methods and compositions for prevention and treatment of diabetic and aged skin
WO2007148078A1 (en) * 2006-06-20 2007-12-27 Lipopeptide Ab Use cathelicidin antimicrobial protein (hcap18 ) as anticancer agent
WO2008073174A2 (en) * 2006-09-08 2008-06-19 The Regents Of The University Of California Antimicrobial therapy
US20090318534A1 (en) * 2006-09-27 2009-12-24 The Regents Of The University Of California Methods and compositions for the treatment of skin diseases and disorders
WO2008103751A2 (en) * 2007-02-20 2008-08-28 The Regents Of The University Of California Antimicrobial and anti-inflammatory therapies and compositions
KR20100049039A (ko) * 2007-06-25 2010-05-11 리포펩타이드 아베 신규한 의약제
EP2200628A2 (en) * 2007-07-15 2010-06-30 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
JP5411857B2 (ja) * 2007-07-30 2014-02-12 ヒールオア・リミテッド 医薬組成物及び関連方法
US20100310514A1 (en) * 2009-06-04 2010-12-09 Chi Hin Cho Anti-Inflammatory Bacteria
EP4089169A1 (en) 2009-10-12 2022-11-16 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
US20120213843A1 (en) * 2009-11-03 2012-08-23 Lipidor Ab Composition for promoting wound healing
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
WO2012150890A1 (en) * 2011-05-02 2012-11-08 Lipidor Ab Antibacterial composition
RU2017127273A (ru) * 2012-03-20 2019-02-04 Хеликс Байомедикс Инк. Короткие антимикробные липопептиды
WO2014004719A2 (en) 2012-06-26 2014-01-03 Worcester Polytechnic Institute Matrix scaffold with antimicrobial activity
EP2821077A1 (en) * 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Lipid nanoparticles for wound healing
CN104513293A (zh) * 2013-09-26 2015-04-15 深圳信立泰药业股份有限公司 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
CN103920137B (zh) * 2014-04-28 2016-03-30 中国药科大学 一种具有抗耐药性革兰阳性细菌作用的药物组合物
WO2015183683A2 (en) * 2014-05-27 2015-12-03 Indiana University Research And Technology Corporation Peptide antagonist of ll-37
CN104984321A (zh) * 2015-07-24 2015-10-21 中国药科大学 人源抗菌肽ll-37在制备治疗或预防血栓性疾病药物中的应用
CN105859867A (zh) * 2016-05-30 2016-08-17 黄石市中心医院 一种人源抗菌肽ll-37突变体及其应用
CN106519042A (zh) * 2016-12-29 2017-03-22 陕西慧康生物科技有限责任公司 人源胶原蛋白与抗菌肽的融合蛋白及其制备方法与编码基因
US20190300575A1 (en) 2018-03-29 2019-10-03 Deetex, LLC Lytic peptide biosensor and methods of making and using the same
CN108659102B (zh) * 2018-04-25 2021-08-17 南方医科大学 具有抗菌及抗炎活性的多肽化合物
ES2799098B2 (es) 2019-06-10 2021-12-10 Univ Madrid Carlos Iii Aptameros agonistas del receptor fpr2 y usos de los mismos
KR102475936B1 (ko) * 2020-10-15 2022-12-09 코스맥스 주식회사 펩타이드 ll-37을 발현하는 효모를 포함하는 화장료 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
CN1091591C (zh) 1994-02-04 2002-10-02 利珀克尔集团公司 亲脂载体制剂
AU691248B2 (en) 1994-02-04 1998-05-14 Scotia Lipidteknik Ab Oil-in-water emulsions
EP0744939B1 (en) 1994-02-04 2002-09-25 Lipocore Holding AB Bilayer preparations made from digalactosyldiacylglycerol containing galactolipid
SE9403055L (sv) 1994-09-13 1996-03-14 Hans G Boman Nytt humant peptidantibiotikum (fall-39) och dess användning
US5654273A (en) * 1994-09-22 1997-08-05 Children's Medical Center Corporation Synducin mediated modulation of tissue repair
JP4048565B2 (ja) * 1996-04-23 2008-02-20 東レ株式会社 「抗ピロリ菌剤」
SE515982C2 (sv) * 1998-03-06 2001-11-05 Lipocore Holding Ab Användning av en olja-i-vatten emulsion som bärare för framställning av en topikal kräm eller lotion
US5925534A (en) * 1998-06-08 1999-07-20 Wako Pure Chemical Industries, Ltd. Method for measuring LDL-cholesterol
AU4013200A (en) * 1999-03-26 2000-10-16 Beth Israel Deaconess Medical Center Method for pr-39 peptide regulated stimulation of angiogenesis
AU2001287628A1 (en) 2000-07-17 2002-01-30 Hansa Medical Ab Antimicrobial agent
CA2416877C (en) 2000-07-27 2013-03-12 Apogene Gmbh & Co. Kg Somatic cloning gene transfer for producing recombinant proteins, cells and organs
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
WO2002060468A2 (en) * 2001-01-30 2002-08-08 University Of Iowa Research Foundation Antiviral activities of primate theta defensins and mammalian cathelicidins
US6835713B2 (en) * 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
WO2002095076A2 (en) * 2001-05-23 2002-11-28 Kabushiki Kaisha Toyota Chuo Kenkyusho Modified polypeptides having protease-resistance and/or protease-sensitivity
EP1358888A1 (en) * 2002-02-28 2003-11-05 Robert Bals The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
GB0223655D0 (en) * 2002-10-10 2002-11-20 Mabtech Ab Method of diagnosis
WO2004056307A2 (en) 2002-12-19 2004-07-08 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
SE0300207D0 (sv) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition

Also Published As

Publication number Publication date
EP1589987A1 (en) 2005-11-02
HK1217661A1 (zh) 2017-01-20
US8936807B2 (en) 2015-01-20
CA2513598A1 (en) 2004-08-12
PT1589987E (pt) 2014-05-28
US7452864B2 (en) 2008-11-18
US20070149448A1 (en) 2007-06-28
CN1744913B (zh) 2010-05-26
JP2006518375A (ja) 2006-08-10
CN105079784B (zh) 2018-05-18
US8506994B2 (en) 2013-08-13
US20130287839A1 (en) 2013-10-31
US20150094256A1 (en) 2015-04-02
JP4750690B2 (ja) 2011-08-17
US8012933B2 (en) 2011-09-06
ZA200505830B (en) 2006-04-26
DK1589987T3 (da) 2014-05-26
CN101838326A (zh) 2010-09-22
CY1115142T1 (el) 2016-12-14
US9125875B2 (en) 2015-09-08
WO2004067025A1 (en) 2004-08-12
ES2467090T3 (es) 2014-06-11
CA2513598C (en) 2015-04-21
SI1589987T1 (sl) 2014-07-31
US20090088382A1 (en) 2009-04-02
CN105079784A (zh) 2015-11-25
EP1589987B1 (en) 2014-04-23
US20110293707A1 (en) 2011-12-01
CN1744913A (zh) 2006-03-08

Similar Documents

Publication Publication Date Title
SE0300207D0 (sv) New use and composition
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
ATE427116T1 (de) Behandlung von bakteriellen infektionen
EP2567971A3 (en) Peptide vaccines comprising Seq Id 80, 100 or 101 for cancers expressing tumor-associated antigens
MX2009012675A (es) Tensioactivos reconstituidos que tienen propiedades mejoradas.
ES2688030T3 (es) Péptidos permeables celulares inhibidores de la ruta de transducción de la señal JNK para su uso en el tratamiento de enfermedades oculares inflamatorias
EP3081214A3 (en) Inhibitors of cellular necrosis
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
NZ607892A (en) Tfpi inhibitors and methods of use
WO2009010968A3 (en) Disease treatment via antimicrobial peptides or their inhibitors
SG10201406288SA (en) Multimeric forms of antimicrobial peptides
DE602004025265D1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
AU2011267081A1 (en) Novel peptides for wound healing
ATE313562T1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
MY147920A (en) Antibacterial and antiviral peptides from actinomadura namibiensis
ATE484290T1 (de) Peptid mit antitumoraler wirkung
AU2003251728A1 (en) Placental growth factor as a target for the treatment of osteoporosis
RS52448B (en) ANTITUMOR PHARMACEUTICAL COMPOSITION CONTAINING SERALIZIN POLYPEPTIDE FRAGMENTS
ATE518878T1 (de) Antimikrobielle peptide
EA200700413A1 (ru) Ариламинкетоны, способ их получения, фармацевтические композиции, содержащие их, и их применение
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
NZ585093A (en) Food material for inhibiting bone resorption
AU2002223983A1 (en) Diastereomeric peptides and pharmaceutical compositions comprising them
RU2008106460A (ru) Антимикробный агент, взаимодействующий с системой комплемента